The combination of an anti-GIPR monoclonal antibody (mAb) and a GLP-1RA has been shown to mediate more pronounced weight loss than either agent alone in preclinical obesity models33. The gene discussed is GIPR; the disease is obesity due to melanocortin 4 receptor deficiency.